Jacqueline McMahon
Family Medicine · Lindenhurst, NYNPI 1407234362
Payments from drug & device makers
Across 138 payments — averaging $21.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$418
- Novo Nordisk$402
- AbbVie$374
- Pfizer$221
- Abbott$169
- Corcept Therapeutics$168
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,950100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $418 |
| Novo Nordisk | 22 | $402 |
| AbbVie | 13 | $374 |
| Pfizer | 11 | $221 |
| Abbott | 8 | $169 |
| Corcept Therapeutics | 7 | $168 |
| Merck | 8 | $130 |
| Regeneron Healthcare Solutions, Inc. | 1 | $118 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $99 |
| GSK | 5 | $97 |
| Shield Therapeutics Inc | 3 | $71 |
| Antares Pharma, Inc. | 3 | $64 |
| Kowa Pharmaceuticals America, Inc. | 4 | $61 |
| Exact Sciences | 3 | $53 |
| Lilly USA, LLC | 2 | $51 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Amgen | 2 | $45 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Esperion Therapeutics, Inc. | 2 | $42 |
| Gilead | 2 | $39 |
| Acella Pharmaceuticals, LLC | 2 | $37 |
| Ironwood Pharmaceuticals, Inc | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $32 |
| Phadia US Inc. | 2 | $27 |
| Lundbeck LLC | 1 | $27 |
| Renalytix AI, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $22 |
| Currax Pharmaceuticals LLC | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,950 in reported general payments places this provider in the 80th percentile of 4,321 family medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 27 | $43,844 |
| OzempicSemaglutide | 35 | $42,829 |
| EliquisApixaban | 28 | $35,535 |
| MounjaroTirzepatide | 23 | $33,119 |
| JanuviaSitagliptin Phosphate | 26 | $31,575 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $18,532 |
| FarxigaDapagliflozin Propanediol | 11 | $17,106 |
| Rosuvastatin Calcium | 195 | $2,750 |
| Diclofenac Sodium | 15 | $1,585 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 43 | $1,303 |
| Levothyroxine Sodium | 95 | $1,262 |
| Losartan Potassium | 106 | $1,187 |
| SynthroidLevothyroxine Sodium | 13 | $1,120 |
| Nebivolol Hcl | 13 | $1,017 |
| Metoprolol Succinate | 77 | $1,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $402 | $42,82935 claims |
| PfizerEliquis | $221 | $35,53528 claims |
| Lilly USA, LLCMounjaro | $51 | $33,11923 claims |
| MerckJanuvia | $130 | $31,57526 claims |
| GSKTrelegy Ellipta | $97 | $18,53217 claims |
| AstraZenecaFarxiga | $418 | $17,10611 claims |
| AbbVieSynthroid | $374 | $1,12013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,321 family medicine providers in New York.
Other family medicine in Lindenhurst
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.